# Pembrolizumab and Lenvatinib in Advanced Cervical Cancer

> **NCT04865887** · PHASE2 · RECRUITING · sponsor: **Georgetown University** · enrollment: 35 (estimated)

## Conditions studied

- Cervical Cancer
- Metastatic Cervical Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT04865887
- **Lead sponsor:** Georgetown University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-10-07
- **Primary completion:** 2026-07
- **Final completion:** 2026-07
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2025-10-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04865887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04865887, "Pembrolizumab and Lenvatinib in Advanced Cervical Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04865887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*